Investor Relations

Corporate Profile

Prelude is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small molecule therapies that target key drivers of cancer cell growth, survival and resistance.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

September 24, 2020
WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share.


More events are coming soon.
Investor Tools